Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Aleve formulation

This article was originally published in The Tan Sheet

Executive Summary

Liquid Gels target active consumers ages 25 to 49 who suffer from back and joint pain, according to Bayer HealthCare. Available now in food, drug and mass retail outlets, Liquid Gels combine the all-day pain relieving power of Aleve (naproxen sodium) with "liquid-fast" speed and convenient dosing, according to the company. "Just two Aleve Liquid Gels can provide this all-day relief, where it would take four or even eight pills with other brands," the firm claims. The gels are sold in 20-, 40-, 80- and 160-count sizes, with suggested retail prices starting at $5.49...

You may also be interested in...



In Brief

Perrigo launches Aleve generic

Kite Strikes CAR-T Access & Discount Deal For Tecartus In England

Health technology assessment body NICE wants Kite to collect more evidence to prove that Tecartus can cure relapsed or refractory mantle cell lymphoma. But in the meantime, it says the CAR-T therapy should be made available on the National Health Service, making UK patients among the first in the world to be offered access to the treatment.

Germany First As Pfenex And Alvogen Biosimilar Forsteo Is Launched

After launching in the US last year, the teriparatide product developed by Pfenex and Alvogen has been introduced in Europa, via commercialization partner Theramex, beginning with Germany.

Topics

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel